Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000075.xml
Download PDF
Semin Respir Crit Care Med
DOI: 10.1055/a-2704-6851
DOI: 10.1055/a-2704-6851
Review Article
Glucocorticoid Treatment in Community-Acquired Pneumonia
Authors
Funding Information P.-F.D. reports funding for academic research projects from the French Ministry of Health and the companies Aerogen and Fisher and Paykel. He has received consulting fees from Aridis Pharmaceutical and conference attendance fees from AOP Health.
Abstract
Despite a fairly large number of comparative trials (which are, however, very heterogeneous), the role of corticosteroids in the adjuvant treatment of community-acquired pneumonia remains controversial. Nevertheless, recent randomized trials with adequate power in intensive care unit patients, albeit with conflicting results, have contributed to clarifying our understanding of this issue. More accurate phenotyping of patients likely to benefit from corticosteroid treatment must now be performed. In COVID-19 pneumonia, their benefit is not in question. For certain specific pathogens, including viral pathogens, their indications must be refined. They are still not recommended for influenza. They appear generally safe for short-term use in select populations.
Publication History
Received: 08 July 2025
Accepted: 17 September 2025
Accepted Manuscript online:
18 September 2025
Article published online:
14 October 2025
© 2025. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024; 403 (10440): 2100-2132
- 2 Ewig S, Birkner N, Strauss R. et al. New perspectives on community-acquired pneumonia in 388,406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64 (12) 1062-1069
- 3 Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med 2014; 371 (17) 1619-1628
- 4 Aston SJ. Pneumonia in the developing world: characteristic features and approach to management. Respirology 2017; 22 (07) 1276-1287
- 5 Cilloniz C, Ferrer M, Liapikou A. et al. Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia. Eur Respir J 2018; 51 (03) 1702215
- 6 Cavallazzi R, Furmanek S, Arnold FW. et al. The burden of community-acquired pneumonia requiring admission to ICU in the United States. Chest 2020; 158 (03) 1008-1016
- 7 File Jr TM, Ramirez JA. Community-acquired pneumonia. N Engl J Med 2023; 389 (07) 632-641
- 8 Vaughn VM, Dickson RP, Horowitz JK, Flanders SA. Community-acquired pneumonia: a review. JAMA 2024; 332 (15) 1282-1295
- 9 Waterer GW, Self WH, Courtney DM. et al. In-hospital deaths among patients with community-acquired pneumonia. Chest 2018; 154 (03) 628-635
- 10 Montón C, Ewig S, Torres A. et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J 1999; 14 (01) 218-220
- 11 Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005; 44 (01) 61-98
- 12 Heming N, Sivanandamoorthy S, Meng P, Bounab R, Annane D. Immune effects of corticosteroids in sepsis. Front Immunol 2018; 9: 1736
- 13 Ayyar VS, Jusko WJ. Transitioning from basic toward systems pharmacodynamic models: lessons from corticosteroids. Pharmacol Rev 2020; 72 (02) 414-438
- 14 Meduri GU, Annane D, Confalonieri M. et al. Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS. Intensive Care Med 2020; 46 (12) 2284-2296
- 15 Quatrini L, Ugolini S. New insights into the cell- and tissue-specificity of glucocorticoid actions. Cell Mol Immunol 2021; 18 (02) 269-278
- 16 Galon J, Franchimont D, Hiroi N. et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 2002; 16 (01) 61-71
- 17 Wagner Jr. HN, Bennett Jr. IL, Lasagna L, Cluff LE, Rosenthal MB, Mirick GS. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp 1956; 98 (03) 197-215
- 18 McHardy VU, Schonell ME. Ampicillin dosage and use of prednisolone in treatment of pneumonia: co-operative controlled trial. BMJ 1972; 4 (5840) 569-573
- 19 Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest 1993; 104 (02) 389-392
- 20 Confalonieri M, Urbino R, Potena A. et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171 (03) 242-248
- 21 El-Ghamrawy AH, Shokeir MH, Esmat AA. Effects of low-dose hydrocortisone in ICU patients with severe community-acquired pneumonia. Egypt J Chest Dis Tuberc 2006; 55: 91-99
- 22 Mikami K, Suzuki M, Kitagawa H. et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007; 185 (05) 249-255
- 23 Snijders D, Daniels JMA, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010; 181 (09) 975-982
- 24 Fernández-Serrano S, Dorca J, Garcia-Vidal C. et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care 2011; 15 (02) R96
- 25 Meijvis SC, Hardeman H, Remmelts HH. et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377 (9782) 2023-2030
- 26 Sabry NA, Omar EE. Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacol Pharm 2011; 2: 73-81
- 27 Nafae RM, Ragab MI, Amany FM, Rashed SB. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egypt J Chest Dis Tuberc 2013; 62: 439-445
- 28 Blum CA, Nigro N, Briel M. et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2015; 385 (9977) 1511-1518
- 29 Torres A, Sibila O, Ferrer M. et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015; 313 (07) 677-686
- 30 Lloyd M, Karahalios A, Janus E. et al; Improving Evidence-Based Treatment Gaps and Outcomes in Community-Acquired Pneumonia (IMPROVE-GAP) Implementation Team at Western Health. Effectiveness of a bundled intervention including adjunctive corticosteroids on outcomes of hospitalized patients with community-acquired pneumonia: a stepped-wedge randomized clinical trial. JAMA Intern Med 2019; 179 (08) 1052-1060
- 31 Wittermans E, Vestjens SMT, Spoorenberg SMC. et al; Santeon-CAP Study Group, Members of the Santeon-CAP Study Group. Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial. Eur Respir J 2021; 58 (02) 2002535
- 32 Meduri GU, Shih MC, Bridges L. et al; ESCAPe Study Group. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med 2022; 48 (08) 1009-1023
- 33 Dequin PF, Meziani F, Quenot JP. et al; CRICS-TriGGERSep Network. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med 2023; 388 (21) 1931-1941
- 34 Angus DC. REMAP-CAP Investigators. Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia: the REMAP-CAP corticosteroid domain randomized clinical trial. Intensive Care Med 2025; 51 (04) 665-680
- 35 Saleem N, Kulkarni A, Snow TAC, Ambler G, Singer M, Arulkumaran N. Effects of corticosteroids on mortality and clinical cure in community-acquired pneumonia. A systematic review, meta-analysis and meta-regression of randomized control trials. Chest 2023; 163 (03) 484-497
- 36 Bergmann F, Pracher L, Sawodny R. et al. Efficacy and safety of corticosteroid therapy for community-acquired pneumonia: a meta-analysis and meta-regression of randomized, controlled trials. Clin Infect Dis 2023; 77 (12) 1704-1713
- 37 Pitre T, Pauley E, Chaudhuri D. et al. Corticosteroids for adult patients hospitalised with non-viral community-acquired pneumonia: a systematic review and meta-analysis. Intensive Care Med 2025; 51 (05) 917-929
- 38 Wirz SA, Blum CA, Schuetz P. et al; STEP Study Group. Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia. Eur Respir J 2016; 48 (04) 1150-1159
- 39 Metlay JP, Waterer GW, Long AC. et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200 (07) e45-e67
- 40 Fine MJ, Auble TE, Yealy DM. et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336 (04) 243-250
- 41 Smit JM, Van Der Zee PA, Stoof SCM. et al. Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials. Lancet Respir Med 2025; 13 (03) 221-233
- 42 Jain S, Self WH, Wunderink RG. et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 373 (05) 415-427
- 43 Ramirez JA, Chandler TR, Furmanek SP. et al; Louisville CAP in the Immunocompromised Study Group. Community-acquired pneumonia in the immunocompromised host: epidemiology and outcomes. Open Forum Infect Dis 2023; 10 (11) ofad565
- 44 Dequin PF, Ramirez JA, Waterer G. What's new with glucocorticoids in severe community-acquired pneumonia?. Intensive Care Med 2023; 49 (11) 1397-1399
- 45 Kaukonen KM, Bailey M, Pilcher D, Cooper DJ, Bellomo R. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med 2015; 372 (17) 1629-1638
- 46 Montull B, Menéndez R, Torres A. et al; NAC Calidad Group. Predictors of severe sepsis among patients hospitalized for community-acquired pneumonia. PLoS One 2016; 11 (01) e0145929
- 47 Annane D, Bellissant E, Bollaert PE. et al. Corticosteroids for treating sepsis in children and adults. Cochrane Database Syst Rev 2019; 12 (12) CD002243
- 48 Pirracchio R, Annane D, Waschka AK. et al. Patient-level meta-analysis of low-dose hydrocortisone in adults with septic shock. NEJM Evid 2023; 2 (06) a2300034
- 49 Annane D, Renault A, Brun-Buisson C. et al; CRICS-TRIGGERSEP Network. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 2018; 378 (09) 809-818
- 50 Heming N, Renault A, Kuperminc E. et al; APROCCHSS investigators, CRICS-TRIGGERSEP network. Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial. Lancet Respir Med 2024; 12 (05) 366-374
- 51 Fitzgerald DB, Waterer GW, Budgeon C. et al. Steroid therapy and outcome of parapneumonic pleural effusions (STOPPE). A pilot randomized clinical trial. Am J Respir Crit Care Med 2022; 205 (09) 1093-1101
- 52 Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2019; 2 (02) CD010406
- 53 Zhou Y, Fu X, Liu X. et al. Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis. Sci Rep 2020; 10 (01) 3044
- 54 Moreno G, Rodríguez A, Reyes LF. et al; GETGAG Study Group. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med 2018; 44 (09) 1470-1482
- 55 Chong WH, Saha BK, Tan CK. Clinical characteristics and outcomes of influenza-associated pulmonary aspergillosis among critically ill patients: a systematic review and meta-analysis. J Hosp Infect 2022; 120: 98-109
- 56 Thomas BJ, Porritt RA, Hertzog PJ, Bardin PG, Tate MD. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Sci Rep 2014; 4: 7176
- 57 Horby P, Lim WS, Emberson JR. et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021; 384 (08) 693-704
- 58 Tomazini BM, Maia IS, Cavalcanti AB. et al; COALITION COVID-19 Brazil III Investigators. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. The CODEX randomized clinical trial. JAMA 2020; 324 (13) 1307-1316
- 59 Angus DC, Derde L, Al-Beidh F. et al; Writing Committee for the REMAP-CAP Investigators. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19. The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA 2020; 324 (13) 1317-1329
- 60 Dequin PF, Heming N, Meziani F. et al; CAPE COVID Trial Group and the CRICS-TriGGERSep Network. Effect of hydrocortisone on 21-day mortality or respiratory support among critically-ill patients with COVID-19. JAMA 2020; 324 (13) 1298-1306
- 61 Munch MW, Myatra SN, Vijayaraghavan BKT. et al; COVID STEROID 2 Trial Group. COVID-STEROID 2 trial group. Effect of 12. . mg vs 6. . mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial. JAMA 2021; 326 (18) 1807-1817
- 62 Bouadma L, Mekontso-Dessap A, Burdet C. et al; COVIDICUS Study Group. High-dose dexamethasone and oxygen support strategies in intensive care unit patients with severe COVID-19 acute respiratory failure: the COVIDICUS randomized clinical trial. JAMA Intern Med 2022; 182 (09) 906-916
- 63 RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk, RECOVERY Collaborative Group. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2023; 401 (10387): 1499-1507
- 64 Munch MW, Granholm A, Maláska J. et al. Dexamethasone doses in patients with COVID-19 and hypoxia: a systematic review and meta-analysis. Acta Anaesthesiol Scand 2024; 68 (02) 146-166
- 65 Salton F, Confalonieri P, Centanni S. et al; MEDEAS Collaborative Group, MEDEAS Collaborative Group. Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS). Eur Respir J 2023; 61 (04) 2201514
- 66 Bozzette SA, Sattler FR, Chiu J. et al; California Collaborative Treatment Group. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323 (21) 1451-1457
- 67 Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev 2015; 2015 (04) CD006150
- 68 Ding L, Huang H, Wang H, He H. Adjunctive corticosteroids may be associated with better outcome for non-HIV Pneumocystis pneumonia with respiratory failure: a systemic review and meta-analysis of observational studies. Ann Intensive Care 2020; 10 (01) 34
- 69 Martin-Loeches I, Torres A, Nagavci B. et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med 2023; 49 (06) 615-632
- 70 Lemiale V, Resche-Rigon M, Zerbib Y. et al. Adjunctive corticosteroids in non-AIDS patients with severe Pneumocystis jirovecii pneumonia (PIC): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 2025; 13 (09) 800-808
- 71 Chaudhuri D, Nei AM, Rochwerg B. et al. 2024 focused update: guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community-acquired pneumonia. Crit Care Med 2024; 52 (05) e219-e233
- 72 Agarwal A, Hunt BJ, Stegemann M. et al. A living WHO guidelines on drugs for COVID-19. BMJ 2020; 370: m3379
- 73 Lockett J, Inder WJ, Clifton VL. The glucocorticoid receptor: isoforms, functions, and contribution to glucocorticoid sensitivity. Endocr Rev 2024; 45 (04) 593-624